Andreas Argyrides
Stock Analyst at Wedbush
(4.32)
# 444
Out of 4,761 analysts
100
Total ratings
48.24%
Success rate
19.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $11.02 | +36.12% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $152.43 | +18.74% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $11.30 | +209.73% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $3.19 | +715.05% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.31 | +434.35% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $1.66 | +924.10% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $16.12 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $42.33 | +145.69% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.95 | +426.32% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $1.40 | +542.86% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $11.24 | +69.04% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $3.01 | +199.00% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.41 | +35.45% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.27 | +188.86% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $106.28 | +110.76% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.16 | +126.55% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.94 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.27 | +451.18% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.76 | +73.61% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $1.07 | +834.58% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $68.25 | +2.56% | 6 | Aug 1, 2023 |
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $11.02
Upside: +36.12%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $152.43
Upside: +18.74%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $11.30
Upside: +209.73%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.19
Upside: +715.05%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.31
Upside: +434.35%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $1.66
Upside: +924.10%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $16.12
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $42.33
Upside: +145.69%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.95
Upside: +426.32%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.40
Upside: +542.86%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $11.24
Upside: +69.04%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $3.01
Upside: +199.00%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.41
Upside: +35.45%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.27
Upside: +188.86%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $106.28
Upside: +110.76%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.16
Upside: +126.55%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.94
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.27
Upside: +451.18%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $5.76
Upside: +73.61%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $1.07
Upside: +834.58%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $68.25
Upside: +2.56%